Key Takeaways

  • Everest Medicines acquired Greater China rights to Lenz Therapeutics’ presbyopia treatment Vizz (LNZ100) from Corxel Pharmaceuticals
  • LNZ100 is currently under regulatory review in China following NDA submission in September 2025, with approval anticipated in the first quarter of 2027

Lenz Therapeutics and Everest Medicines have expanded their partnership around presbyopia treatment Vizz (aceclidine ophthalmic solution) 1.44%, with Everest acquiring Greater China rights to the product through an asset purchase agreement with Corxel Pharmaceuticals.

The transaction transfers to Everest the rights and obligations under Corxel’s April 2022 licensing agreement with Lenz for Vizz, known in China as LNZ100. The deal covers mainland China, Hong Kong, Macao, and Taiwan and positions Everest to lead development, regulatory activities, manufacturing, and commercialization efforts across the region.

The move comes as LNZ100 advances through the Chinese regulatory process. A new drug application (NDA) was submitted to the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) in September 2025, with approval anticipated in the first quarter of 2027.

For Lenz, the agreement preserves the economic terms of its existing partnership structure. The company remains eligible to receive up to $85 million in remaining regulatory and commercial milestones, along with tiered royalties ranging from the mid-single digits to low double digits on net sales in Greater China. Lenz is also entitled to additional payments associated with the execution of the transaction between Corxel and Everest.

“LNZ100 is a differentiated asset with meaningful clinical value and strong commercial potential in the treatment of presbyopia,” said Yifang Wu, chairman of Everest Medicines. “As the presbyopia patient population continues to grow, significant unmet needs remain in noninvasive treatment options.”

Vizz, which was approved by the FDA in July 2025, became the first FDA-approved aceclidine-based eye drop for presbyopia in the United States.